Our Company

GBT is working to discover, develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease

Our goal is to transform the treatment of sickle cell disease (SCD), an overlooked rare condition, and help address the urgent needs of the community. Our mission is driven by the historical lack of understanding and attention given to SCD. Although the fundamental cause of SCD has been understood for decades, therapeutic innovation and access to care has significantly lagged.

GBT’s medicine is the first treatment approved by the FDA to target an underlying cause of SCD. We are developing additional investigational treatments that have the potential to better the lives of patients.

Our commitment to the SCD community

We are driven by a deep and urgent desire to improve the care of SCD patients. Beyond developing medicines, we are working to shine a bright light on the disparities and inequalities faced by people living with SCD. To this end, in July 2019 we launched Sickle Cell Speaks, a national campaign focused on breaking down stigmas associated with SCD.

Our history: From the beginning, we have been committed to changing the treatment paradigm for SCD.

Jun 2017

Voxelotor Gets PRIME Designation from EMA for SCD

Voxelotor became the first potential treatment for SCD to be accepted for the EU’s new Priority Medicines (PRIME) designation, enabling frequent and early interactions with the EMA to accelerate evaluation and potential marketing approval.

JAN 2017

First Patient Enrolled in GBT’s SCD HOPE Study

The HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study was designed to assess the efficacy of voxelotor in producing meaningful clinical improvements in anemia.

AUG 2012

Voxelotor (GBT440) Discovered

GBT began testing GBT440 in 2012 to understand its mechanism of action. This molecule would later be named voxelotor.

FEB 2011

Global Blood Therapeutics, Inc. (GBT), is founded

The company was founded to develop medicines that could make a transformative impact, and SCD was our first focus.